Loading
Axelopran is a pill that blocks opioid effects outside the brain. Glycyx Therapeutics is testing it with immunotherapy in head and neck cancer in people who take opioids for pain.
Axelopran was first developed for opioid-induced constipation and reached phase 2b in that use, according to Glycyx Therapeutics, which now develops it as an adjunct to checkpoint inhibitors. Glycyx sponsors NCT07662720 (MORALE-HN01), a phase 1/2 study of axelopran with pembrolizumab in recurrent or metastatic head and neck squamous cell carcinoma in patients taking opioids for cancer pain, not yet recruiting in the registry. A separate phase 2 trial run by HealthPartners Institute, NCT07354919, tests axelopran in patients with advanced cancers on opioids. The anti-tumour evidence is preclinical.
Blocks mu-opioid receptors outside the brain, which Glycyx proposes reverses opioid-driven suppression of anti-tumour immunity while leaving central pain relief intact. Connects to Mu-opioid receptor.
1.Axelopran slips into a pocket on Mu-opioid receptor.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Axelopran" OR ABSTRACT:"Axelopran") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Axelopran, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/